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A B S T R A C T   
Amongst the most important discoveries in ALS pathobiology are the works demonstrating that multiple cell 
types contribute to disease onset and progression. However, a significant limitation in ALS research is the 
inability to obtain tissues from ALS patient brain and spinal cord during the course of the disease. In vivo 
modeling has provided insights into the role of these cell subtypes in disease onset and progression. However, in 
vivo models also have shortcomings, including the reliance on a limited number of models based upon hereditary 
forms of the disease. Therefore, using human induced pluripotent stem cells (iPSC) reprogrammed from somatic 
cells of ALS patients, with both hereditary and sporadic forms of the disease, and differentiated into cell subtypes 
of both the central nervous system (CNS) and peripheral nervous system (PNS), have become powerful com-
plementary tools for investigating basic mechanisms of disease as well as a platform for drug discovery. Motor 
neuron and other neuron subtypes, as well as non-neuronal cells have been differentiated from human iPSC and 
studied for their potential contributions to ALS pathobiology. As iPSC technologies have advanced, 3D modeling 
with multicellular systems organised in microfluidic chambers or organoids are the next step in validating the 
pathways and therapeutic targets already identified. Precision medicine approaches with iPSC using either 
traditional strategies of screening drugs that target a known pathogenic mechanism as well as “blind-to-target” 
drug screenings that allow for patient stratification based on drug response rather than clinical characteristics are 
now being employed.   
1. Introduction 
One of the most significant limitations in understanding disease 
mechanisms in ALS and, therefore, in the investigation of potential ALS 
therapeutics, lies in our inability to obtain tissues from ALS patient brain 
and spinal cord during the course of the disease. Autopsy tissues from 
ALS patients are important in providing a window into the disease, but 
tissues obtained at endstage do not reflect disease mechanisms as they 
evolve. Access to tissues during the critical time periods of early diag-
nosis would allow for a more detailed understanding of disease pro-
gression by offering a window into how disease-relevant pathways are 
activated temporally and anatomically. Animal models of ALS have 
proven valuable in our understanding of how different cell subtypes 
contribute to disease but because these models are largely based upon 
uncommon ALS gene mutations, are not particularly predictive of the 
disease as a whole nor has their study resulted in broad therapeutic 
success. Therefore, the identification first of human embryonic stem 
cells (ESC) by Thomson et al. in 1998 [1] and later the development of 
techniques for reprogramming from somatic cells to induced pluripotent 
stem cells (iPSC) by Takahashi et al. in 2007 [2], has offered in-
vestigators the capacity to utilize these cells for modeling disease 
mechanisms in real time. Since that time, the field of iPSC biology has 
progressed at an impressive pace and a number of other methods for 
reprogramming somatic cells have been identified—each with its own 
advantages and limitations [3–5]. 
Induced pluripotent stem cells can be differentiated into all somatic 
cell types and, for the purposes of ALS research, cell subtypes of both the 
central nervous system (CNS) and peripheral nervous system (PNS). 
Motor neuron and other neuron subtypes, astrocytes, oligodendrocytes, 
microglia, muscle, and Schwann cells have all been differentiated from 
human iPSC and studied for their potential contributions to ALS 
pathobiology. Perhaps most importantly, because iPSC can be reprog-
rammed from somatic cells (usually peripheral blood mononuclear cells 
or skin fibroblasts) during adulthood, they can be obtained from ALS 
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patients with genotypically and phenotypically heterogeneous ALS 
presentations; offering insights into the spectrum not only of familial 
ALS but of the larger sporadic ALS population as well. 
In this review, we discuss the different cell types that have been 
proposed as playing a role in ALS pathogenesis and progression based 
upon human observations and animal modeling. This is highlighted by 
the observations that pathologies in a number of neuronal cell subtypes, 
particularly in the context of ALS/FTD, continue to redefine the breadth 
of neural cell involvement. The second section highlights how these 
multiple cell types derived from human iPSC can be utilised to identify 
new therapeutic targets for drug treatment. Creative phenotypic read-
outs using iPSC have begun to facilitate drug discovery that is cell- 
specific or genotype-specific. Precision medicine approaches using 
iPSC have been applied to ALS to allow for patient stratification based on 
drug response rather than clinical characteristics and we conclude with 
an assessment of future advances beyond our current strategies 
including multicellular 2D and 3D-modeling of these cultures that may 
be used to further refine therapeutic approaches. 
2. Cell subtype involvement in ALS pathogenesis 
Amongst the most important discoveries in ALS pathobiology are the 
works demonstrating that multiple cell types contribute to disease onset 
and progression. These observations, detailed in a growing body of 
literature, are not only important in understanding disease mechanisms 
but are exciting in their prospects for translational research. Since 
numerous cell types contribute to disease, the proposition that 
numerous pathways could be involved in different stages of the disease 
offers hope for the identification of several therapeutic targets. 
While traditionally thought of as a motor neuron disease primarily 
involving corticospinal and spinal motor neurons, the evolution in our 
understanding of ALS pathobiology now suggests that other neuronal 
cell subtypes (sometimes producing ALS with Frontotemporal Dementia 
(FTD)) are susceptible as well. 
2.1. Frontotemporal Dementia and ALS—beyond motor neurons 
Frontotemporal dementia, manifested by cognitive and behavioral 
changes, is found in 5–15 % of ALS patients [6]. The cognitive 
dysfunction that occurs along with ALS are notable in suggesting that 
pathologies are not limited to motor neurons but a heterogeneous 
pattern of association between motor and cognitive impairment. 
ALS/FTD pathologically share the presence of TDP-43 deposition that 
begins in the corticospinal motor neuron (CSMN) and spinal motor 
neurons and then progresses to involve neurons of the frontal and 
anterior parietal regions, and brainstem reticular formation. This is 
followed by pathology in the anterior frontal and basal forebrain, lateral 
thalamus and substantia nigra and finally, in the most advanced cases, 
TDP-43 deposition in neurons of anterior temporal lobe and hippo-
campus [7]. 
Several genes have been identified as part of the ALS/FTD spectrum 
including those associated with autophagy (SQSTM1, UBQLN2, VCP, 
OPTN), mitochondrial function (CHCHD10), and RNA metabolism 
(C9orf72, HNRNPA1, HNRNPA2B1) [8]. However, the C9orf72 hex-
anucleotide expansion (HRE) in an intronic region of this gene has been 
identified as the most common mutation in familial ALS/FTD patients 
[9–11]. 
To model ALS associated with the HRE in the C9orf72 gene, Chew 
et al. used an AAV vector to induce robust expression of the HRE 
delivered intracerebroventricularly (ICV) into neonatal mice. This 
resulted in the development of nuclear RNA foci, inclusions of DPRs, as 
well as TDP-43 pathology. This was accompanied by the loss of cortical 
neurons suggesting that, as with seen with mutations in SOD1, alsin, and 
TDP-43, the expression of the C9orf72 HRE is also associated with 
cortical neuron pathology [12]. Similarly, BAC transgenic mice carrying 
the C9orf72 HRE construct developed pathology in layer V of the cortex 
associated with CSMN loss as well as a behavioral phenotype that 
included reduced survival and/or motor abnormalities [13]. However, 
other C9orf72 models expressing the HRE have not shown evidence of 
neurodegeneration [14,15]. The discrepancies in some of these findings 
likely reflect methodological differences in the in vivo approaches to 
expressing the C9orf72 HRE as well as the complexities of modeling an 
in vivo network. Given some of the complexities of C9orf72 HRE 
modeling in vivo, induced pluripotent stem cells from C9orf72 HRE pa-
tients have been used extensively as an adjunct for modeling ALS as 
discussed in the sections below. 
2.2. Corticospinal and spinal motor neurons-hallmarks of ALS 
pathobiology 
Corticospinal motor neuron (CSMN) dysfunction and loss is a well- 
known clinical and pathological feature in ALS patients [16–18]. How-
ever, CSMN biology has presented challenges for ALS modeling, possibly 
because human cortex-spinal cord connectivity is via monosynaptic 
connections while the mouse has different patterns of connectivity [19], 
resulting in less dramatic pathological and phenotypically-observable 
changes that could be attributed to corticospinal motor neuron 
dysfunction in mouse models. There are, however, in vivo studies 
demonstrating CSMN dysfunction in ALS models and, therefore, high-
light an underappreciated pathology amenable to study [20–23]. 
Spinal motor neuron dysfunction is often recognized as the hallmark 
feature of ALS manifesting as weakness, muscle atrophy, hypotonia, 
muscle fasciculations and electrophysiological features of muscle 
denervation [24,25]. Because of the prominent spinal motor neuron loss 
present in the transgenic mutant SOD1 (mSOD1) mouse, much of our 
knowledge about motor neuron pathobiology has leaned heavily on this 
model. Moreover, since this was the first mouse model of ALS [26], 
numerous potential therapeutic approaches have been aimed at neuro-
protection and positive influences on behavioral outcomes. While the 
vast majority of therapeutics studied in this model have not proven 
translatable to human therapies [27], in the right context it remains a 
useful model of motor neuron disease. 
Additionally, in several genetic models of ALS (SOD1, TDP-43, FUS, 
UBQLN2, Profilin), using promoters known to drive gene expression in 
neurons (Thy1, PrP), the incorporation of ALS genes with known mu-
tations is sufficient to produce varying degrees of motor neuron disease 
or motor coordination impairment in some form—conceptually high-
lighting that spinal motor neuron dysfunction by itself is a central 
feature associated with motor phenotypes [28]. Furthermore, deletion 
of mSOD1 only in motor neurons using Cre/Lox strategies has contrib-
uted to the widely held belief that motor neuron dysfunction and/or 
death is the initiating event in ALS whereas disease progression is sub-
sequently modulated by other non-neuronal cell subtypes [29]. 
2.3. Astrocytes 
Reactive astrocytosis is a hallmark of ALS and other neurodegener-
ative diseases, and long thought to be a pathological byproduct of 
neuron loss rather than a significant contributor to disease itself. 
Therefore, the assertion, in the 1990s by Rothstein and colleagues, that 
ALS astrocytes could contribute to ALS was important in highlighting 
the non-cell autonomous contributions of these cells to ALS pathogen-
esis. Their focus was on the demonstration that ALS astrocytes had a 
reduction in the astrocyte-specific glutamate transporter EAAT2 [30, 
31]. This phenomenon was demonstrated in human ALS brain and spinal 
cord tissues as well as animal models of ALS and provided an important 
bridge for further therapeutic study [32]. Since then, astrocytes are 
known to be important in the interplay amongst other ALS-relevant cell 
subtypes. 
In animal models of ALS, the transgenic overexpression of mSOD1 in 
astrocytes alone was not sufficient to produce motor neuron loss, 
although the glial fibrillary acidic protein (GFAP) promoter used to 
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overexpress mSOD1 in astrocytes may not have been sufficient to initiate 
an ALS phenotype or produce pathology in motor neurons [33]. A 
number of studies have since provided evidence to suggest that ALS 
astrocytes are mediators of disease progression in vivo [34–37] including 
a recent study by Guttenplan et al. that broadens the role of astrocytes 
through the demonstration that neuroinflammatory reactive astrocytes, 
responding to microglially released IL-1α, TNFα, and C1q, are respon-
sible for disease progression in ALS and suggests that gliosis itself may be 
a therapeutic target for neurodegeneration [38]. However, perhaps the 
most versatile studies linking ALS astrocytes to motor neuron toxicity 
have come from elegant in vitro studies using iPSC (as discussed below). 
2.4. Oligodendrocytes 
Oligodendrocytes are primarily recognized for their myelin produc-
tion and their capacity for wrapping around axons to improve conduc-
tion. Therefore, disorders primarily affecting myelin, like multiple 
sclerosis, have received the most attention as demyelination is evident 
radiographically and its sequelae have unique phenotypic representa-
tions. However, oligodendrocyte pathology with patchy regions of 
demyelination has also been observed in ALS autopsy tissues [39]. These 
findings are also supported in mSOD1 mouse models of ALS where 
oligodendrocyte pathology and death were accompanied by prolifera-
tion of oligodendrocyte precursor cells (OPC). This phenomenon is 
accompanied by the loss of the monocarboxylate 1 (MCT1) transporter 
which appears to also play a role in oligodendrocyte-mediated motor 
neuron support by providing lactate under conditions of metabolic stress 
[39–41]. The effect of oligodendrocyte dysfunction in ALS models is 
quite robust, since deleting mSOD1 specifically from oligodendrocytes 
has resulted in a significant improvement in motor neuron pathology 
and mSOD1 mouse survival [39]. 
2.5. Microglia and macrophages 
As the CNS’s resident immune cell, microglia are typically observed 
in a resting state unless perturbed by an insult in which they become 
activated [42]. In patients with ALS, techniques using [11C]-PBR28, a 
PET radiotracer that selectively binds to the translocator protein (TSPO), 
and is upregulated in activated microglia and reactive astrocytes shows 
a correlation of reactive microgliosis in regions of pathology in ALS 
patients [43,44] and the involvement of microglia as part of the neu-
roinflammasome in ALS, has been the focus of intense research and the 
target of several ALS-relevant therapeutic trials [45]. 
Historically, a somewhat simplified nomenclature has identified two 
types of microglia: M1, which are believed to promote toxicity through 
the release of pro-inflammatory cytokines and chemokines and M2, 
identified as having neuroprotective qualities through the release of 
anti-inflammatory chemokines and other functions including promoting 
phagocytosis of debris or promoting tissue repair [46–48]. However, a 
sophisticated molecular and genetic interrogation has identified a novel 
microglial type (enriched in Trem2 expression), Disease Associated 
Microglia (DAM), in neurodegeneration [49]. These DAM have been 
noted to increase in spinal cords of SOD1G93A mice as well as motor 
cortices of ALS patients [50] and may have differing roles in neuro-
protection early in the disease course. The implications of DAM acti-
vation as disease progresses remains under investigation [51]. 
In ALS mouse models, activated microglia are a consistent feature of 
spinal cord pathology. The potential importance of microglia in medi-
ating neuroinflammatory responses has been demonstrated through the 
genetic manipulations [52] of key microglially-mediated factors as well 
as drugs that target microglial-mediated neuroinflammatory cascades. 
Important early work using LoxSOD1G37R/CD11b-Cre mice to selec-
tively reduce SOD1 in microglia resulted in a prolonged disease pro-
gression thus suggesting that microglia are mediators of disease 
progression after onset [29]. However, one limitation of these studies is 
that most of these in vivo manipulations have taken place in mSOD1 mice 
and therefore the relevance of this pathway to sporadic ALS, while 
clearly important, may be difficult to extrapolate from these studies 
[53]. Interestingly, microglia that have decreased C9orf72 expression 
show aberrations in microglial function including defects in lysosomal 
trafficking and profiles in both human C9orf72 ALS patients and 
C9orf72-/- mice suggesting enhanced neuroinflammation [54]. 
In a recent set of experiments, Chiot et al. dissected the contribution 
of peripheral macrophages to ALS progression in two ALS mouse 
models. Interestingly, modifying peripheral macrophages from an ALS 
phenotype to a neuroprotective phenotype, downregulated inflamma-
tion along peripheral nerves and resulted in neuroprotection and pro-
longed survival. This study elegantly demonstrated that peripheral 
macrophages do not infiltrate the CNS as previously hypothesized but 
emphasized that macrophages in the periphery can have an effect on 
motor neuron loss occurring centrally [55]. 
2.6. Other non-neuronal cellular contributions to ALS 
Although not discussed more extensively in this review, animal 
modeling has also demonstrated a role for T-lymphocytes [56–58], 
myocytes [59–62], Schwann cells [63–66], NG2 glia [67], and pericytes 
[68–70] offering the potential to use iPSC modeling for the discovery of 
additional cell-specific contributions throughout the CNS and PNS. 
In vivo ALS modeling has provided us with enormous insights 
regarding cell-specific etiologies of ALS but is somewhat limited in its 
reliance on modeling genetic forms of ALS, the complexity of the in-
teractions amongst numerous cell types and networks, expense, and 
duration of study. Therefore, in light of these relative limitations, there 
are opportunities for complementing in vivo modeling by using iPSC- 
based platforms in the investigation of ALS mechanisms and 
therapeutics. 
3. Using somatic cell reprogramming for therapeutic approaches 
The first report of iPSC-derived MNs harbouring a TDP-43 mutation 
(TDP-43 M337 V) [71] showed mild changes in TDP-43 localization or 
aggregate formation and increases in cell death compared to controls 
under stress conditions. Since the early studies, the field has seen a 
remarkable improvement in differentiation protocols yielding purer and 
more mature MN cultures. These have, in fact, improved from a yield of 
20 % [72] to 80–90 % HB9+ cells [73] with mature electrophysiological 
properties [74]. At the same time, key cues for neuronal patterning have 
been identified, specifically resulting in limb-innervating MNs [75]. In a 
disease where different neuronal populations and cell types are affected 
in different ways and others are spared, in vitro culture conditions can 
substantially affect the resulting phenotype and, therefore, reproduc-
ibility across studies. Regardless of these limitations, iPSC-derived MNs 
carrying mutations in ALS-linked genes have highlighted the importance 
of some key pathological pathways that have been recently reviewed 
[76] and have led to new approaches for drug discovery and patient 
stratification, reviewed in the following sections. 
3.1. Drug discovery 
The heterogeneity of ALS in terms of site of disease onset, duration 
and severity might underlie the activation of different disease mecha-
nisms all converging in MN death. Our ability to understand which cell 
populations and pathways are involved in neurotoxicity is likely to 
inform effective therapeutic interventions. While recent efforts are 
concentrating on multicellular co-culture systems, present drug 
screenings have mainly focused on targeting MNs and using phenotypic 
readouts consistent across various laboratories and common to a variety 
of ALS patient genotypes: TDP-43 proteinopathy, protein homeostasis 
impairment and hyperexcitability (Table 1). 
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3.2. TDP-43 proteinopathy 
One of the first drug screening studies using iPSC-derived MNs was 
conducted by Egawa et al. [77], who found that MN from ALS patients 
carrying mutant TDP-43 formed cytosolic aggregates similar to those 
seen in postmortem tissues and exhibited shorter neurites. In addition, 
MNs displayed increased mutant protein aggregates bound to the spli-
ceosomal factor SNRPB2 and widespread dysregulation of splicing and 
transcription. This prompted the authors to perform a small drug 
screening focusing on molecules targeting histone modification or RNA 
splicing, which led to the identification of a histone acetyltransferase 
inhibitor called anacardic acid. Treatment with this drug rescued the 
abnormal ALS MN phenotype reported in the study, thus providing the 
first proof of principle that iPSC-derived cells can be effectively used to 
identify therapeutic compounds [77]. Another approach to target 
TDP-43 mislocalization was identified by Fang et al. who used puro-
mycin treatment to obtain TDP-43 cytoplasmic puncta in mutant TDP-43 
iPS MNs. Excitingly, molecules with planar moieties, which act as 
nucleic acid intercalating molecules, prevented stress granule localiza-
tion of TDP-43 and reduced its cytoplasmic accumulation [78]. 
Due to the presence of TDP-43 proteinopathy in sALS, Burkhardt 
et al. used this as readout for patient stratification and drug screening in 
sporadic disease [79]. The authors reprogrammed 16 sporadic fibroblast 
cell lines and differentiated them into MNs, they then characterised the 
cells for TDP-43 aggregates and found that only 3 out of the 16 lines 
displayed abnormal staining for this marker. Although variability in the 
cell model cannot be excluded, this finding could be descriptive of a 
subgroup of sporadic patients where TDP-43 proteinopathy is involved, 
for example, in the early stage of disease. This pathogenic phenotype 
was then utilised to screen for FDA approved compounds that can lower 
the amount of TDP-43 aggregates in both familial and sporadic cases 
[79]. 
3.3. Proteostasis 
Protein aggregation is a hallmark of several neurodegenerative dis-
orders and, as such, proteostasis is considered an appealing therapeutic 
target [80]. The link between ALS and proteostasis dysregulation is 
highlighted by the number of ALS-linked genes which are involved in 
this pathway including SQSTM1, OPTN, TBK1 and VCP. 
Small molecules activating autophagy and the proteasome have been 
investigated in the context of ALS as promising therapeutics to decrease 
accumulation of misfolded proteins [81]. Once more, iPSC MNs dis-
playing TDP-43 mislocalization through endogenous or induced mech-
anisms have been used to identify potential drug candidates where 
TDP-43 proteinopathy was reduced through manipulation of proteo-
stasis rather than the RNA-related mechanisms as discussed above. 
Barmada et al. demonstrated that in primary cortical neurons the 
amount of TDP-43 proteinopathy was proportional to neurotoxicity and 
that activation of autophagy via fluphenazine and methotrimeprazine 
successfully increased TDP-43 aggregate clearance and rescued 
neuronal survival in primary rodent neurons, as well as patient-derived 
mutant TDP-43 MNs and astrocytes [82]. 
Similarly, a recent study by Khosravi et al. has demonstrated that 
expression of poly-GA in transgenic cell models, as well as patient cells, 
promotes TDP-43 aggregation by inhibiting the proteasome in a cell- 
autonomous fashion as well as in a non-cell autonomous paradigm of 
cell-to-cell dipepetide repeat (DPR) transmission. The authors found 
that protein aggregation can be prevented by boosting proteasome ac-
tivity with rolipram [83]. Consistent with these reports, MNs derived 
from patients carrying mutant FUS and displaying cytoplasmic protein 
aggregates were preserved by treatment with autophagy-inducing 
drugs, such as the mTOR inhibitors torkinib and PQR309, currently in 
clinical trial for cancer treatment [84]. 
The above-mentioned studies collectively suggest that activation of 
autophagy or the proteasome are promising therapeutic approaches for 
the treatment of ALS, however, in vivo studies indicate that several 
factors should be considered. Firstly, the stage of the disease when 
treatment commences and duration of treatment. Genetic inhibition of 
autophagy in motor neurons of mutant SOD1 mice revealed that auto-
phagy can be protective early in disease progression, but detrimental at 
later stages [85]. In addition, most autophagy activators act through 
mTOR inhibition, which is likely to affect several other pathways 
beyond autophagy, including protein synthesis and immunosuppres-
sion. In conclusion, future studies targeting proteostasis in vitro should 
be complemented with in vivo tests, which are more likely to highlight 
the limitations of these therapeutic approaches, as they give the op-
portunity to observe the effect of drugs in a complex system over time 
and in various disease stages. 
3.4. Electrophysiological abnormalities 
Similar targeted approaches have been applied to other consistent 
pathophysiological characteristics, such as electrophysiological defects, 
which occur early in disease development in patients [86]. Indeed, 
electrophysiological alterations have been detected in iPSC-derived MNs 
from patients carrying various mutations, thus demonstrating impair-
ment in cell functionality. Studies from various groups have reported 
that patient MNs are initially hyperexcitable and then they become 
hypoexcitable, potentially due to a progressive decrease in 
voltage-activated Na+ and K+ currents causing a progressive loss of 
synaptic activity [87]. These electrophysiological changes were recor-
ded in iPSC-derived MNs from both mutant TDP-43 and C9orf72 cells, 
even in absence of decreased viability [87]. Due to the relevance of these 
Table 1 
Therapeutic agents identified using iPSC-derived MNs.  
Pathway targeted. Cell type Mutation Therapeutic agent Therapeutic stage Reference 
RNA metabolism MN TDP-43 anacardic acid in vitro Egawa et al. [77] 
Stress granule formation MN TDP-43 nucleic acid intercalating molecules and cardiac 
glycosides 
in vitro Fang et al. [78] 
Stress granule formation MN sALS cardiac glycosides in vitro Burkhardt et al. 
[79] 
Autophagy MN and 
astrocytes 
TDP-43 fluphenazine and methotrimeprazine in vitro Barmada et al. 
[82] 
Autophagy MN FUS torkinib and PQR309 in vitro Marrone et al. 
[84] 
Proteasome activation MN C9orf72 rolipram in vitro Khosravi et al. 
[83] 
Hyperexcitability MN SOD1 ezogabine Phase II clinical trial Wainger et al. [74] 
Src/abl inhibition MN SOD1, TDP-43, C9orf72, 
sALS 
bosutinib Phase I clinical trial Imamura et al. 
[90] 
Dopamine D2 receptor 
agonism 
MN FUS, TDP-43, sALS ropinirole Phase I/IIa clinical 
trial 
Fujimori et al. 
[92]  
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early alterations in ALS pathology and thanks to the ability in moni-
toring these changes in patients throughout disease, therapeutic ap-
proaches targeting these functional alterations are particularly 
appealing. One recent example is the identification of retigabine/ezo-
gabine, a Kv7 channel activator, able to rescue mSOD1 iPSC-MN hy-
perexcitability and improve MN survival [74]. Impairment of this ion 
channel was subsequently validated in a study using a high-throughput 
all-optical screening approach, where single MNs can be recorded and 
analyzed within a complex network [88]. Indeed these findings were 
recently confirmed in a phase 2 randomized clinical trial in which a total 
of 65 ALS participants were randomized to placebo (23), 600 mg/d of 
ezogabine (23), and 900 mg/d of ezogabine (19 participants)(Clin-
icalTrials.gov Identifier:NCT02450552). Patients treated with ezoga-
bine displayed a decrease in cortical and spinal MN excitability as 
predicted by the in vitro results [89]. This latest study is an example of 
how, even if with limitations, iPSC-derived cells can guide target iden-
tification and inform therapeutic approaches. 
3.5. Precision medicine approaches 
Recently, a different approach, based on “blind-to-target” drug 
screenings, has been applied to ALS to allow for patient stratification 
based on drug response rather than clinical characteristics. These ap-
proaches use the underlying concept that we can reliably and consis-
tently measure disease-relevant pathological hallmarks in patient- 
derived cells and these can be used to screen drugs that correct a 
certain phenotype, thus allowing us to identify a target and, potentially, 
a therapeutic compound at the same time. 
Such efforts often focus on drug repurposing, using libraries of FDA 
approved drugs, with the aim to streamline the drug approval process. 
One of the main targets identified with this approach is the Src/c-Abl 
pathway identified by Imamura et al. [90]. The authors developed an 
inducible, high-throughput MN differentiation protocol that allowed 
screening more than 1400 compounds, targeting various pathways, in 
one iPSC patient-derived mSOD1 line. The screening returned 27 hits, 
highly enriched for molecules targeting the Src/c-Abl pathway, which 
improved MN survival. Selected hits, amongst which bosutinib 
(currently in clinical trial UMIN:000036295) [91], were then screened 
on 11 additional ALS iPSC lines from sporadic patients or carrying 
SOD1, TDP-43 and C9orf72 mutations to verify neuroprotection. 
As new cell reprogramming and differentiation protocols for high- 
throughput screenings are developed, as well as the ability to optimise 
and scale up reliable readouts, we might be able to stratify patients more 
accurately based on drug responses against several parameters. An 
elegant example of such an approach is the study by Fujimori et al. [92], 
where a staged high-throughput drug screening assessed more than 
1200 molecules for their effect on 6 different pathological readouts, 
from cell death to stress granule formation and protein aggregates, in 
one FUS iPSC line. Ninety-five selected hits were then taken forward in a 
TDP-43 line, where 9 were confirmed as neuroprotective and, after 
scoring the hits for brain permeability, potential side-effects and effi-
cacy, ropinirole was selected as top hit. This compound was then tested 
in 24 out of 32 different sporadic ALS lines that were stratified according 
to the 6 pathological readouts assessed for the screening. The 24 iPSC 
MN lines were selected based on their in vitro “disease severity”. Inter-
estingly, the authors found that only 16 of the 24 MN lines displayed 
improvement in cell death and protein aggregation upon ropinirole 
treatment. Whether this patient-specific drug response translates in the 
patient population and what specific characteristics and biomarkers 
could be used to stratify the population ‘a priori’ are still open questions 
and present challenges that we will have to be resolved in order to 
advance this precision medicine approach, as other fields, such as cancer 
and asthma, have achieved. 
4. The future of disease modeling and drug discovery 
The progress achieved in the past 5 years has led to new clinical trials 
testing drugs identified using iPSC-derived patient MNs. The complex 
multifactorial nature of ALS, however, indicates that therapies targeting 
only MNs might have a limited effect. As highlighted in the first part of 
this review article, in fact, several other cell types play a key role in MN 
death. Hence, effective disease-modifying therapies are likely to require 
investigation of pathogenic mechanisms and therapeutic targets in 
patient-derived models that mirror the complex interaction between 
different cell types. 
4.1. Co-culture systems 
Reports implicating non-neuronal cells and, in particular, astrocytes 
in the pathology of ALS have prompted a number of studies aiming to 
identify the impact of these cells on motor neuron survival. As previ-
ously discussed, in vivo studies have been crucial in highlighting the role 
of glia in disease progression [29,34] and, potentially disease onset [93]. 
In vitro co-culture studies have been important in uncovering astro-
cyte neurotoxicity initially from mSOD1 mouse models [94,95] and 
subsequently from post-mortem human samples harbouring SOD1 mu-
tations or isolated from sporadic ALS cases [96,97]. These studies 
showed for the first time that astrocyte toxicity is a widespread disease 
mechanism affecting familial as well as sporadic ALS patients and that 
astrocyte toxicity is associated with soluble factors [96,97]. 
Whereas opposing results have emerged when investigating the 
neurotoxic properties of iPSC-derived astrocytes harbouring TDP-43 
mutations in vitro [98], astrocyte toxicity is a well-established and 
consistent phenotype in other familial forms of disease, including 
C9orf72 [99,100] and VCP-linked [101] ALS, as well as sporadic disease 
[36,99]. One of the most pressing questions in the field focuses around 
the origin of this toxicity and the factors mediating MN death, with the 
aim of developing therapeutic approaches. A plethora of mechanisms 
have been proposed [102], but the role of astrocytes in MN death is 
likely to be related to multiple factors, some of which exert toxicity, 
while others underlie overall astrocyte dysfunction, leading to a toxic 
lack of support. Recent studies have, in fact, reported widespread 
changes in astrocyte transcriptome [100] and secretome [103], as well 
as their ability to maintain calcium homeostasis due to Connexin 43 
dysregulation [104], indicating that these cells are likely to be failing in 
several physiological functions essential to support MN survival. 
Amongst these, recent studies have reported severe metabolic dysfunc-
tion in C9orf72 patient-derived astrocytes [105,106], particularly linked 
to defects in adenosine deaminase, thus leading to healthy MN death in a 
co-culture system. Neuroprotection in this system was achieved via 
supplementation of inosine. Besides providing metabolic support to 
neurons, astrocytes are also known to be essential in supporting neurite 
growth and maintenance, as well as dampening oxidative stress through 
secreted factors [107]. Recent studies have shown that C9orf72 astro-
cytes are defective in secreting anti-oxidant enzymes [108], as well as 
miRNAs supporting neurite maintenance in co-cultured MNs [103]. 
Neurite growth and MN survival could both be rescued by supplemen-
tation of miRNA 494−3p in the co-cultures, thus identifying this miRNA 
as a potential therapeutic target. Future studies should focus on under-
standing the impact of therapies targeting these pathways in vivo. 
In addition, patient-derived astrocytes seem to be able to induce in 
healthy MNs a number of pathological features we have previously 
described as cell-autonomous [82,87]. For example, C9orf72 
patient-derived astrocytes can induce electrophysiological defects in 
healthy MNs by triggering loss of action potential output through a 
decrease in the magnitude of voltage-activated Na+ and K+ currents 
[109]. Similarly, Madill et al. [110], report that conditioned medium 
from C9orf72 patient astrocytes can induce accumulation of p62 in MNs, 
which is, in turn, alleviated by rapamycin treatment. Interestingly, 
Rajpurohit et al. propose activation of the opposite mechanism in 
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mutant SOD1 astrocyte, which trigger hyperactivation of autophagy, 
thus resulting in MN stress and death [111]. Such a complex neurotoxic 
interaction could be unravelled through recent co-culture blind--
to-target drug screening approaches [112], where neuroprotective drugs 
could shed light on the pathways involved in the toxic interaction be-
tween two cell types. 
An alternative approach to unravelling the nature of this toxic 
interaction has recently been taken by Mishra et al. [113], where the 
authors specifically focused on ligand-mediated interactions between 
MNs and astrocytes. By using an integrative analysis approach that 
combines proteomics and regulatory network analysis, the authors 
identified the interaction between astrocyte secreted Amyloid Precursor 
Protein (APP) and death receptor-6 (DR6) on MNs the top predicted 
ligand-receptor pair responsible for astrocyte-mediated MN death. This 
toxic interaction was confirmed using murine mutant SOD1 astrocytes 
as well as human sporadic astrocytes. 
Although clear evidence from post-mortem tissue and mouse models 
of ALS has uncovered the contribution of oligodendrocytes and micro-
glia/macrophages to disease as presented in previous sections, in vitro 
studies from patient-derived cells are still scarce, probably due to the 
length and complexity of the protocols that lead to functional and 
mature cells. 
Consistent with in vivo data [39], oligodendrocytes derived from ALS 
patients did not present any maturation impairment [114,115], how-
ever, they induced MN death in vitro and displayed impaired lactate 
release in the medium, associated with decreased expression of MCT1 
[115]. Surprisingly, lactate supplementation was not sufficient to rescue 
MN survival in co-culture, thus indicating that metabolic defects are 
only one aspect of cell dysfunction. Interestingly, 
oligodendrocyte-mediated MN death could be rescued in SOD1 and 
sporadic ALS cases via SOD1 knockdown only if protein suppression was 
achieved in OPCs [115], thus suggesting that functional impairment 
might have a short therapeutic window in these cells. Recently, a 
high-throughput platform including iPSC-derived MNs and myelinating 
oligodendrocytes has been generated [116], thus opening new oppor-
tunities for future drug screening efforts. 
Reliable and efficient protocols to study the properties of patient- 
derived microglia and macrophages are still under development. As 
highlighted earlier in this review, in vivo studies and co-culture systems 
from the mSOD1 mouse models have shown that microglia mainly 
contribute to disease through inflammation [117], thus focusing ther-
apeutic efforts towards anti-inflammatory approaches. Exciting new 
findings showed that iPSC-derived M2 macrophages from C9orf72 and 
sALS patients exert an anti-inflammatory effect on M1 macrophages and 
boost ALS Tregs [118], thus demonstrating the potential for 
immune-cell-based therapy to mitigate inflammation in ALS. 
4.2. 3D disease modeling 
Multicellular systems organised in microfluidic chambers or orga-
noids are the next step to validate the pathways and therapeutic targets 
already identified and are a potential platform for further discovery. 
Such models are being developed not only to study the interaction be-
tween neurons and glia, but also to model the neuromuscular junction 
(NMJ), considering that failure in this specialised synapse is one of the 
first signs of disease. 
Recently, 3D NMJ models have been developed with the aim to 
characterize this complex system and interrogate the interaction be-
tween MNs and muscles. In 2018 Osaki et al. [119] successfully obtained 
formation of motor units by using microfluidic chambers where MN 
spheroids and muscle bundles were plated in different compartments of 
the chamber. This system recapitulated the motor unit loss observed in 
ALS patients [120] and recovery was obtained by boosting autophagy or 
inhibiting the Src/c-Abl pathway, thus leading to decreased TDP-43 
proteinopathy. Further insight has been gained through these initial 
NMJ systems with regards to the selective vulnerability of MNs compare 
to sympathetic neurons (SNs) [121], which are mainly spared in ALS. 
Healthy NMJs displayed a higher level of stationary mitochondria in 
MNs compared with SNs, consistent with the finding that the NMJ is 
highly dependent upon mitochondrial respiration, while SN synapses 
rely on both mitochondria and glycolysis for ATP production. This in-
dicates that mitochondrial dysfunction might have a higher impact on 
NMJ function compared to SN synapse. 
Alongside microfluidics and bioprinting, which provide structure 
and better system control, organoids have emerged as a developing 
resource to study cell-to-cell interaction under basal pathological con-
ditions in diseases like AD, where organoids seem to have reliably 
retained specific profiles of protein aggregation [122,123] and HD 
[124]. 
Interesting future avenues for ALS are the emerging spinal cord 
spheroids, fabricated using magnetic nanoparticles. These are posi-
tioned in a three-dimensional hydrogel construct using magnetic bio-
printing, thus resulting in structures that provide both localized cell–cell 
interactions and long-distance projections that mimic in vivo structure 
[125]. 
5. Conclusions 
Twelve years after the generation of the first iPSC-derived MNs from 
ALS patients, significant progress has been made in disease modeling 
and therapeutics discovery thanks to the development of more efficient 
and reliable differentiation protocols. In addition, our ability to model 
not only MN pathology, but also the pathological changes affecting non- 
neuronal cells, will allow for the identification of new and potentially 
more effective therapeutic targets. These advancements have already 
led to the identification of compounds in clinical trials including: 
bosutinib, ropinirole [91], and ezogabine. The use of patient-derived 
cells, however, is not limited to mechanistic and drug discovery 
studies, but they have also supported biomarker studies. In fact, 
iPSC-derived MNs have also been used to show that there is a correlation 
between intracellular and extracellular poly-GP [126], thus supporting 
that secreted CSF poly-GP is a surrogate of intracellular protein and, 
therefore, a promising pharmacodynamic marker for trials of antisense 
oligonucleotides in ALS clinical trials. 
Moreover, the generation of patient-derived cellular models has 
offered unprecedented opportunities to overcome the limitations pre-
sented by models driven by transgene overexpression, including the 
possibility of obtaining insight into sporadic disease. This is either 
determined by complex genetic factors that we are still far from 
unravelling and modeling, or epigenetic changes accumulated over a 
lifetime. Unfortunately, however, some reprogramming techniques do 
not preserve epigenetic changes, thus limiting our ability to model sALS. 
Direct reprogramming methodologies overcome, at least in part, this 
limitation and allow the production of neurons [127] and astrocytes 
[128] that retain some epigenetic features and, therefore, are likely to be 
more suitable for modeling aging and disease. Other challenges include 
reproducing the phenomenon of aging cells in their embryonic pheno-
type [129–131], consistently reproducing results amongst laboratories 
using iPSC, and overcoming the costs of producing ALS iPSC on a scale 
that allows for the implementation of drug screening strategies [132]. 
Indeed, achieving consistency and reproducibility between different 
laboratories will be crucial in developing effective neuroprotective 
compounds. One of the challenges in evaluating and comparing the 
findings from different studies over the past twelve years, in fact, partly 
lies in the lack of details regarding iPSC differentiation efficiency, cul-
ture purity and maturity, as well as quantification of other neuronal and 
non-neuronal cell types in each study. 
As these challenges are addressed, the use of human iPSC to model 
cell-specific contributions to ALS offers the potential for versatility by 
providing nearly limitless combinations of culture conditions that can be 
analyzed in a relatively efficient manner for understanding disease 
mechanisms and screening therapeutic compounds. This is 
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complemented by in vivo modeling using a number of different animal 
models that will continue to help inform about the complexity of these 
interactions for ALS therapeutic development. 
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